O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed glioblastoma multiforme (GBM), including the following:
• * Small or large cell GBM
• * Gliosarcoma
• Temozolomide-resistant disease, as defined by the following:
• * Unequivocal evidence of tumor progression after receiving adjuvant temozolomide therapy for 5 consecutive days every 28 days for ≥ 2 courses
• Must have failed prior radiotherapy
• * Progression must be documented by MRI (while on a stable steroid dose for ≥ 5 days) ≥ 12 weeks after completion of radiotherapy
• Must have paraffin-embedded tissue blocks or ≥ 4 unstained paraffin-embedded microscope slides available from diagnosis
• PATIENT CHARACTERISTICS:
• Karnofsky performance status 60-100%
• Life expectancy \> 8 weeks
• White blood cell (WBC) ≥ 3,000/mm(³)
• Absolute neutrophil count ≥ 1,500/mm(³)
• Platelet count ≥ 100,000/mm(³)
• Hemoglobin ≥ 10 g/dL (transfusion allowed)
• Aspartate aminotransaminase (AST) \< 2 times upper limit of normal (ULN)
• Bilirubin \< 2 times ULN
• Creatinine \< 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min
• No significant medical illness that, in the opinion of the investigator, would preclude study compliance
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No significant active cardiac, hepatic, renal, or psychiatric disease
• No other known active malignancy except for nonmelanoma skin cancer or carcinoma in situ of the cervix
• No active infection requiring intravenous (IV) antibiotics
• No disease that would obscure toxicity or alter drug metabolism
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Recovered from prior temozolomide
• Prior resection of recurrent or progressive tumor allowed if all the following criteria are met:
• * Recovered from prior surgery
• * Residual disease after resection of recurrent tumor by computed tomography (CT) scan or magnetic resonance imaging (MRI) (while on a stable steroid dose for ≥ 5 days) ≤ 96 hours OR ≥ 4 weeks after surgery
• At least 12 weeks since prior radiotherapy
• No other prior therapy (i.e., polifeprosan 20 with carmustine implant \[Gliadel wafers\] or nitrosoureas)
• No other concurrent chemotherapy, radiotherapy, immunotherapy, or investigational agents